National and Kapodistrian University of Athens
Διερεύνηση των κλινικών και οικονομικών συνεπειών από τη χρήση των ΠΕΚΦΚ και των ΠΕΚΦΚ που συνδέονται με ενταφιαζόμενο κώδωνα χημειοθεραπείας
Abstract
dc:descriptionABSTRACT Introduction: Peripherally inserted central catheters (PICCs) and PICC-port systems are used for the administration of anticancer treatment. However, they differ in terms of insertion technique, patient experience, follow-up requirements, complications, and direct insertion cost. Aim: The aim of this study was to compare PICCs and PICC-port systems regarding patient experience, technical insertion characteristics, documented complications and device dysfunctions, follow-up requirements, and direct insertion cost in adult oncology patients. Materials and Methods: A retrospective comparative cohort study was conducted among 164 adult oncology patients, of whom 101 had a PICC and 63 had a PICC-port inserted between 2015 and 2020. Categorical variables were compared using the chi-square test or Fisher’s exact test, while continuous or ordinal variables were compared using the independent-samples t-test or the Mann–Whitney U test, according to their distribution. A secondary composite pain–difficulty score was developed from four individual items and demonstrated acceptable internal consistency (Cronbach’s α= 0.798). Supplementary simple linear regression models were also performed, with catheter type as the sole independent variable. Results: The two groups did not differ significantly in the recorded demographic and basic clinical characteristics. Patients with a PICC reported lowerpain during device insertion and removal, greater comfort during insertion, and less difficulty during device removal compared with patients with a PICC-port (all p < 0.001). The composite pain–difficulty score was also lower in the PICC group. In the simple linear regression model, PICC-port use was associated with a mean 1.676- point higher pain–difficulty score compared with PICC use (95% CI: 1.584–1.768; p <0.001). PICC-port use was also associated with a €68.41 higher direct insertion cost (95% CI: €51.95–€84.87; p < 0.001) and a 3.919 cm longer subcutaneous tunnel length(95% CI: 3.719–4.118; p < 0.001) compared with PICC use. Insertion-related adverse events were documented in 6.3% of patients with a PICC-port and in none of the patients with a PICC (Fisher’s exact test, p = 0.021). All patients required scheduled device follow-up, with planned intervals of seven days for PICCs and 21 days for PICC-port systems. No statistically significant differences were observed between the two groups regarding thrombosis or thrombophlebitis, central line-associated bloodstream infection, catheter-related bloodstream infection, occlusion, accidental device removal, overall device satisfaction, or the need for telephone or in-person contact with the vascular access team following insertion. Conclusions: PICC use was associated with a lower immediate procedurerelated burden, lower direct insertion cost, and a lower documented frequency of insertion-related adverse events compared with PICC-port use. However, these findings were based on unadjusted comparisons and do not establish causal or overall superiority of one catheter type over the other. Device selection should therefore be individualized according to the patient’s clinical condition, the type and anticipated duration of treatment, follow-up requirements, available healthcare resources, and patientpreferences.Keywords: PICC, PICC-port, oncology patients, central venous access, direct insertioncost, patient experience.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Efstathopoulou, Kyparissia-Efthymia
- Ευσταθοπούλου, Κυπαρισσία-Ευθυμία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62678